Welcure Drugs and Pharmaceuticals Ltd.

As of March 31, 2026, Welcure Drugs and Pharmaceuticals Ltd. carries a market capitalization of 296.63M, placing it among publicly traded companies globally. Its enterprise value stands at 290.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Welcure Drugs and Pharmaceuticals Ltd. has 1.24B shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.06, and the price-to-book ratio stands at 0.31.

These figures are as of March 31, 2026. The EV/Sales ratio of 0.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 290.86M versus a market cap of 296.63M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Welcure Drugs and Pharmaceuticals Ltd. maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Welcure Drugs and Pharmaceuticals Ltd. posted a negative return on equity (ROE) of -17.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.37, reflecting losses generated across the asset base. Inventory turnover of 2.25 indicates how many times Welcure Drugs and Pharmaceuticals Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Welcure Drugs and Pharmaceuticals Ltd. recorded 110.55M in income tax expense. The company reported a pretax loss of -59.35M and -169.91M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Welcure Drugs and Pharmaceuticals Ltd.'s stock has declined approximately 74.65% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.28.

Over the twelve months ended March 31, 2026, Welcure Drugs and Pharmaceuticals Ltd. generated 3.66B in revenue and converted that into -169.91M in net income, yielding earnings per share of -0.18. EBITDA reached -73.85M, while operating income came in at -73.99M.

As of March 31, 2026, Welcure Drugs and Pharmaceuticals Ltd. holds 5.76M in cash and equivalents against - - in total debt, resulting in a net debt position of -5.76M. Total book value stands at 970.20M, with working capital of -556.20M providing operational flexibility.

Over the twelve months ended March 31, 2026, Welcure Drugs and Pharmaceuticals Ltd. posted a gross margin of 11.68, reflecting its pricing power and cost economics. The operating margin of -2.02 and net profit margin of -4.65 provide insight into operational efficiency.

Welcure Drugs and Pharmaceuticals Ltd.'s most recent stock split took place on October 16, 2025 with a 1:11 split ratio.